MET and pancreatic neoplasm: In vitro experiments revealed ligand-independent MET activation through EGFR-MET co-immunoprecipitation in hepatocellular carcinoma cells [26] and promotion of metastatization by MET and IGF-1R cross-talk in pancreatic cancer [27].